Table 4.
Correlations between early change in bone resorption marker sCTX and clinical assessments at last follow-up
| Δ0 to 3 sCTX Z-score | ||
|---|---|---|
| Assessment at last follow-up a | correlation | P-value |
| BASDAI (range 0 to 10) | -0.388 | 0.000 |
| ASDASCRP | -0.463 | 0.000 |
| Physician's GDA (range 0 to 10) | -0.321 | 0.001 |
| Patient's GDA (range 0 to 10) | -0.260 | 0.010 |
| ESR (mm/h) | -0.273 | 0.006 |
| CRP (mg/l) | -0.288 | 0.004 |
| BASFI (range 0 to 10) | -0.268 | 0.008 |
| Chest expansion (cm) | 0.260 | 0.010 |
| Modified Schober test (cm) | -0.031 | 0.762 |
| Occiput to wall distance (cm) | 0.095 | 0.350 |
| Lateral lumbar flexion L (cm) | 0.096 | 0.346 |
| Lateral lumbar flexion R (cm) | 0.169 | 0.097 |
| ASQoL (range 0 to 18) | -0.296 | 0.003 |
Data of 105 AS patients were analyzed.
See Tables 1 and 3 for abbreviations.
a Defined as at three years of TNF-α blocking therapy or at the moment of treatment discontinuation